3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
10
Non-Muscle Invasive Bladder Neoplasms
6
Peritoneal Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Transitional Cell
3
Appendiceal Neoplasms
3
Anus Neoplasms
2
Urothelial Carcinoma of the Bladder
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Rectal Neoplasms
1
Pseudomyxoma Peritonei
1
Peritoneal Diseases
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Necrosis
1
Male Urogenital Diseases
1
HIV Infections
1
Gastrointestinal Neoplasms
1
Female Urogenital Diseases
1
Anal Canal Carcinoma
1
Interventions
pembrolizumab
36
Bevacizumab
25
Cyclophosphamide
23
Blood Specimen Collection
19
Nivolumab
17
Standard of Care
15
Carboplatin
15
Paclitaxel
14
atezolizumab
13
Gemcitabine
13
Exercise
13
Pemetrexed
11
Fluorouracil
11
Doxorubicin
11
Cisplatin
11
Cetuximab
10
Radiotherapy
9
Oxaliplatin
9
Magnetic Resonance Spectroscopy
9
Leucovorin
9
Docetaxel
9
130-nm albumin-bound paclitaxel
9
durvalumab
8
abemaciclib
8
Temozolomide
8
Surveys and Questionnaires
8
Rituximab
8
Prednisone
8
Biopsy
8
olaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Mitomycin
×
90 days
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled